Public Employees Retirement System of Ohio Acquires Shares of 98,188 Becton, Dickinson and Company $BDX

Public Employees Retirement System of Ohio bought a new position in shares of Becton, Dickinson and Company (NYSE:BDX) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 98,188 shares of the medical instruments supplier’s stock, valued at approximately $14,859,000.

Several other hedge funds and other institutional investors also recently modified their holdings of BDX. Brighton Jones LLC lifted its position in shares of Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after buying an additional 877 shares during the last quarter. Empowered Funds LLC grew its position in Becton, Dickinson and Company by 20.4% in the first quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock valued at $1,827,000 after acquiring an additional 1,354 shares during the last quarter. United Bank raised its stake in Becton, Dickinson and Company by 23.9% during the second quarter. United Bank now owns 5,149 shares of the medical instruments supplier’s stock worth $887,000 after acquiring an additional 993 shares in the last quarter. Marshall Wace LLP lifted its holdings in shares of Becton, Dickinson and Company by 365.1% in the second quarter. Marshall Wace LLP now owns 31,876 shares of the medical instruments supplier’s stock worth $5,491,000 after acquiring an additional 25,022 shares during the last quarter. Finally, NewEdge Advisors LLC lifted its holdings in shares of Becton, Dickinson and Company by 34.7% in the second quarter. NewEdge Advisors LLC now owns 23,501 shares of the medical instruments supplier’s stock worth $4,048,000 after acquiring an additional 6,058 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Up 0.1%

NYSE:BDX opened at $189.71 on Monday. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $193.07. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. The company has a market cap of $52.27 billion, a PE ratio of 57.14, a P/E/G ratio of 13.36 and a beta of 0.19. The firm’s 50 day simple moving average is $166.14 and its 200 day simple moving average is $160.20.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.14 by $0.09. The firm had revenue of $4.98 billion during the quarter, compared to analysts’ expectations of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company’s revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the company posted $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, research analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be given a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 126.51%.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP Roland Goette sold 2,438 shares of Becton, Dickinson and Company stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the transaction, the executive vice president directly owned 14,856 shares of the company’s stock, valued at approximately $2,686,559.04. The trade was a 14.10% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of the stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the sale, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $20,380,155. The trade was a 3.63% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 9,105 shares of company stock valued at $1,590,208 in the last quarter. 0.40% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

BDX has been the subject of a number of research analyst reports. UBS Group initiated coverage on shares of Becton, Dickinson and Company in a research report on Tuesday, July 28th. They set a “buy” rating and a $190.00 price objective for the company. Bank of America cut their target price on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a research report on Friday, June 12th. Piper Sandler upped their price target on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a “neutral” rating in a report on Friday, August 7th. Citigroup reissued a “buy” rating on shares of Becton, Dickinson and Company in a report on Thursday, August 13th. Finally, Jefferies Financial Group restated a “buy” rating and set a $210.00 price objective on shares of Becton, Dickinson and Company in a research report on Thursday, August 6th. Eight research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $185.67.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.